Novel Insights and Therapeutics for Parkinson Disease

Parkinson’s disease is that the primary growth driver of the worldwide Parkinson’s disease therapeutics. According to the estimates of the World Health Organization, the worldwide prevalence of Parkinson’s disease was valued at over 10 million in 2012. The share of the world’s population above the age of 65 years can increase from 7-membered in 2000 to 16 PF in 2050. The therapeutics of Parkinson Disease includes designing a Clinical trial for parkinsonian disorders, Outcome of clinical trials in PSP, MSA and CBD, therapeutic options for mood, Cognition and Psychosis, Treatment of Parkinson patient with psychosis,  Rehabilitation therapies for Parkinson Disease, Medical and Surgical treatment, RNAi and antibody-based therapeutic approaches, therapies targeting autophagy in movement disorders, Isogenic human-induced pluripotent stem cells, Human embryonic stem cell-based therapies in Parkinson disease,  Novel proteinopathy based tracers for diagnosis, Therapeutic developments in the treatment of cognitive impairment,  Morphological and molecular basis of levodopa-induced dyskinesia’s, Electrophysiological, and their therapeutic implications.

  • Designing a clinical trial for atypical parkinsonian disorders
  • Outcome of clinical trials in MSA, PSP and CBD
  • Therapeutic options for mood, cognition and psychosis in Parkinson’s disease
  • How to treat anxiety, depression and apathy
  • How to treat the Parkinson’s disease patient with cognitive impairment and psychosis
  • Medical and surgical treatment of Parkinsons disease
  • Rehabilitation therapies for Parkinsons disease
  • RNAi and antibody-based therapeutic approaches
  • Therapies targeting autophagy in movement disorders
  • Isogenic human-induced pluripotent stem cells
  • Human embryonic stem cell-based therapies in Parkinsons disease
  • Novel proteinopathy based tracers for diagnosis
  • Therapeutic developments in the treatment of cognitive impairment
  • Gene therapy for Parkinsons disease and movement disorders
  • Electrophysiological, morphological and molecular basis of levodopa-induced dyskinesias and their therapeutic implications

Related Conference of Novel Insights and Therapeutics for Parkinson Disease

Novel Insights and Therapeutics for Parkinson Disease Conference Speakers